source
- Verdiva Bio halts phase 2 oral GLP-1 trial after enrolling only eight participantsVerdiva Bio announced it is ending its phase 2 study of VRB-101, a once‑weekly oral GLP‑1 candidate, after the trial fell far short of its enrollment target. The study was intended to evaluate swi…
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncologyGilead Sciences announced a licensing agreement with Vir Biotechnology to access Vir's dual-masked PRO-XTEN T-cell engager platform for oncology. Under the deal, Vir will discover, design and opti…